DataExpo GAKG DeepReport Navigation

Copyright©2015-2024 Acemap, Inc. Shanghai Jiao Tong University. All rights reserved.

沪ICP备18028330号

ML

Marie‐Cécile Le Deley

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Gilles Vassal

Université Paris-Saclay

Jacques Grill

Institut Gustave Roussy

Pascale Varlet

Centre Hospitalier Sainte-Anne

Darren Hargrave

Great Ormond Street Hospital

Tim Jaspan

Nottingham University Hospitals NHS Trust

Maura Massimino

Fondazione IRCCS Istituto Nazionale dei Tumori

Amedeo A. Azizi

Medical University of Vienna

Chris Jones

Institute of Cancer Research

Adela Cañete

Hospital Universitari i Politècnic La Fe

Frank Saran

University of South Australia

Cooperative Institutions

Inserm

Institut Gustave Roussy

Centre Oscar Lambret

Centre National de la Recherche Scientifique

Université Paris-Saclay

Assistance Publique – Hôpitaux de Paris

Institut Curie

Université Paris-Sud

Université Paris Cité

Centre Léon Bérard

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors

Investigational New Drugs (2017)

Rastislav Bahleda Marie‐Cécile Le Deley Apexa Bernard Shalini Chaturvedi Michael J. Hanley

Tolerability

Pharmacodynamics

Regimen

Anorexia

10.1007/s10637-017-0531-3

Cite

Citations (10)

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

BMC Medicine (2023)

Coralie Courtinard Sophie Gourgou William Jacot Matthieu Carton Olivier Guérin

Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification).

Clinical endpoint

Progression-free survival

10.1186/s12916-023-02754-5

Cite

Citations (8)

Le rôle des cohortes d’expansion dans les essais de phase I en cancérologie : des recommandations du HUB phase I

Bulletin du Cancer (2015)

Monia Ezzalfani Audrey Emmanuelle Dugué Caroline Mollévi Marina Pulido Franck Bonnetain

10.1016/j.bulcan.2014.10.001

Cite

Citations (6)

Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study

European Journal of Cancer (2010)

Birgit Geoerger Julia Chisholm Marie‐Cécile Le Deley Jean‐Claude Gentet C. Michel Zwaan

Refractory (planetary science)

10.1016/j.ejca.2010.09.015

Cite

Citations (42)

Supplementary Figure from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Nicolas Penel Sylvie Bonvalot André-Michel Bimbai Alexandra Meurgey François Le Loarer

Supplementary Figure from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Value (mathematics)

10.1158/1078-0432.22488020

Cite

Citations (0)

Supplementary Data from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Nicolas Penel Sylvie Bonvalot André-Michel Bimbai Alexandra Meurgey François Le Loarer

Supplementary Data from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Value (mathematics)

10.1158/1078-0432.22488035

Cite

Citations (0)

Supplementary Figure from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Nicolas Penel Sylvie Bonvalot André-Michel Bimbai Alexandra Meurgey François Le Loarer

Supplementary Figure from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Value (mathematics)

10.1158/1078-0432.22488032

Cite

Citations (0)

Supplementary Data from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Nicolas Penel Sylvie Bonvalot André-Michel Bimbai Alexandra Meurgey François Le Loarer

Supplementary Data from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis

Value (mathematics)

10.1158/1078-0432.22488035.v1

Cite

Citations (0)

Supplementary Table and Figure Legends from Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of <i>STAG2</i> and <i>TP53</i> Mutations

Franck Tirode Didier Surdez Xiaotu Ma Matthew Parker Marie‐Cécile Le Deley

<p>List of supplementary tables and figures.</p>

Table (database)

10.1158/2159-8290.22530086

Cite

Citations (0)

National clinical-biological prospective cohort of incident cases of aggressive fibromatosis, AF (ALTITUDES)

Annals of Oncology (2019)

Thomas Ryckewaert Nicolas Penel Marie‐Cécile Le Deley J-C. Thery Emilie Decoupigny

Natural history study

10.1093/annonc/mdz283.068

Cite

Citations (0)

More pages